Towards a blood-stage vaccine for malaria: Are we following all the leads?

Nature Reviews Immunology

Volumn 1, Issue 2, 2001, Pages 117-125

  Good, Michael F ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ANIMAL; ANTIGENIC VARIATION; BIOLOGICAL MODEL; CELLULAR IMMUNITY; ERYTHROCYTE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; ISOLATION AND PURIFICATION; MALARIA; PARASITOLOGY; PLASMODIUM; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENIC VARIATION; ANTIGENS, PROTOZOAN; ERYTHROCYTES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; MALARIA; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MODELS, IMMUNOLOGICAL; PLASMODIUM; PROTOZOAN PROTEINS; T-LYMPHOCYTES;

EID: 0035525357     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/35100540     Document Type: Review

References (115)

1. Good, M. F., Kumar, S. & Miller, L. H. The real difficulties for malaria sporozoite vaccine development. Nonresponsiveness and antigenic variation. Immunol. Today 9, 351-355 (1988).
2. Good, M. F., Zevering, Y., Currier, J. & Bilsborough, J. 'Original antigenic sin', T cell memory, and malaria sporozoite immunity: an hypothesis for immune evasion. Parasite Immunol. 15, 187-193 (1993).
3. Taylor, R. R. et al. Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int. Immunol. 8, 905-915 (1996).
4. Riley, E. M. The role of MHC- and non-MHC-associated genes in determining the human immune response to malaria antigens. Parasitology 112, S39-S51 (1996).
5. Plotkin, S. L. & Plotkin, S. A. in Vaccines (eds Plotkin, S. A. & Mortimer, E. A.) 1-7 (W. B. Saunders Co., Philadelphia, 1988).
6. Good, M. F. & Doolan, D. L. Immune effector mechanisms in malaria. Curr. Opin. Immunol. 11, 412-419 (1999).
7. Doolan, D. L. & Hoffman, S. L. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165, 1453-1462 (2000).
8. Kaslow, D. C. Transmission-blocking vaccines: uses and current status of development. Int. J. Parasitol. 27, 183-189 (1997).
9. Miller, L. H., Good, M. F. & Milon, G. Disease pathogenesis in malaria. Science 264, 1878-1883 (1994). This paper provides a concise overview of the pathogenesis of malaria.
10. Baird, J. K. Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum. Ann. Trop. Med. Parasitol. 92, 367-390 (1998).
11. Marsh, K. & Howard, R. J. Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants. Science 231, 150-153 (1986). This paper provides some of the best early insights into the nature of natural immunity to malaria and provides an explanation for why prolonged exposure to the parasite is required for this to develop.
12. Newbold, C. I., Pinches, R., Roberts, D. J. & Marsh, K. Plasmodium falciparum: the human agglutinating antibody response to the infected red cell surface is predominantly variant specific. Exp. Parasitol. 75, 281-292 (1992).
13. Greenwood, B. M. et al. Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa. Trans. R. Soc. Trop. Med. Hyg. 81, 478-486 (1987).
14. Biggs, B. A. et al. Antigenic variation in Plasmodium falciparum. Proc. Natl Acad. Sci. USA 88, 9171-9174 (1991).
15. Baruch, D. I. et al. Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 82, 77-87 (1995).
16. Su, X. Z. et al. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 82, 89-100 (1995).
17. Smith, J. D. et al. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82, 101-110 (1995). References 15-17 describe the cloning of the variant antigens of P. falciparum, which enables us to develop rational molecular approaches to understanding pathogenesis and natural immunity to malaria.
18. Brandt, E. R. et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nature Med. 6, 455-459 (2000).
19. Sercarz, E. E. et al. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11, 729-766 (1993).
20. Good, M. F., Branigan, J., Smith, G. & Houghten, R. A. Peptide immunization can elicit malaria protein-specific memory helper but not proliferate T cells. Importance of cryptic epitopes in consideration of vaccine design. Pept. Res. 3, 110-115 (1990).
21. Amante, F. H., Crewther, P. E., Anders, R. F. & Good M. F. A cryptic T cell epitope on the apical membrane antigen 1 of Plasmodium chabaudi adami can prime for an anamnestic antibody response: implications for malaria vaccine design. J. Immunol. 159, 5535-5544 (1997).
22. Lo-Man, R. et al. A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy. Cancer Res. 59, 1520-1524 (1999).
23. + lines propagated with tetanus toxoid or with synthetic tetanus toxin sequences. J. Autoimmun. 9, 79-88 (1996).
24. Bou-Habib, D. C. et al. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68, 6006-6013 (1994).
25. Robert-Guroff, M. et al. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization. J. Virol. 68, 3459-3466 (1994).
26. Gamain, B., Miller, L. H. & Baruch, D. I. The surface variant antigens of Plasmodium falciparum contain cross-reactive epitopes. Proc. Natl Acad. Sci. USA 98, 2664-2669 (2001).
27. Good, M. F., Kaslow, D. C. & Miller, L. H. Pathways and strategies for developing a malaria blood-stage vaccine. Annu. Rev. Immunol. 16, 57-87 (1998).
28. Holder, A. A. in Malaria Vaccine Development: A Multiimmune Response Approach (ed. Hoffman, S. L.) 77-104 (American Society for Microbiology Press, Washington, DC, 1996).
29. Holder, A. A. Malaria vaccines. Proc. Natl Acad. Sci. USA 96, 1167-1169 (1999).
30. Deans, J. A. et al. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 KD merozoite antigen. Parasite Immunol. 10, 535-552 (1988).
31. Collins, W. E. et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am. J. Trop. Med. Hyg. 51, 711-719 (1994).
32. Crewther, P. E., Matthew, M. L., Flegg, R. H. & Anders, R. F. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect. Immun. 64, 3310-3317 (1996).
33. Anders, R. F. & Saul, A. Malaria vaccines. Parasitol. Today 16, 444-447 (2000).
34. Kumar, S. et al. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect. Immun. 68, 2215-2223 (2000).
35. Egan, A. F., Blackman, M. J. & Kaslow, D. C. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive,-exposed, and/or-rechallenged-Aotus vociferans monkeys. Infect. Immun. 68, 1418-1427 (2000).
36. Ling, I. T., Ogun, S. A. & Holder, A. A. Immunization against malaria with a recombinant protein. Parasite Immunol. 16, 63-67 (1994).
37. Daly, T. M. & Long, C. A. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J. Immunol. 155, 236-243 (1995).
38. Tian, J.-H. et al. Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. J. Immunol. 157, 1176-1183 (1996).
39. + T cells. J. Immunol. 159, 3400-3411 (1997).
40. Chitarra, V., Holm, I., Bentley, G. A., Petres, S. & Longacre, S. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 Å resolution, a highly protective malaria vaccine candidate. Mol. Cell 3, 457-464 (1999).
41. Blackman, M. J., Heidrich, H. G., Donachie, S., McBride, J. S. & Holder, A. A. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J. Exp. Med. 172, 379-382 (1990).
42. Herrera, M. A. et al. Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum γ-interferon levels with protection. Infect. Immun. 60, 154-158 (1992).
43. Lawrence, G. et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 18, 1925-1931 (2000).
44. Genton, B. et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 18, 2504-2511 (2000).
45. Alonso, P. L. et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344, 1175-1181 (1994).
46. D'Alessandro, U. et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 346, 462-467 (1995).
47. Nosten, F. et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet 348, 701-707 (1996).
48. Bojang, K. A. et al. An efficacy trial of the malaria vaccine SPf66 in Gambian infants - second year of follow-up. Vaccine 16, 62-67 (1998).
49. Metzger, W. G. et al. Serological responses of Gambian children to immunization with the malaria vaccine SPf66. Parasite Immunol. 21, 335-340 (1999).
50. Guevara Patino, J. A., Holder, A. A., McBride, J. S. & Blackman, M. J. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J. Exp. Med. 186, 1689-1699 (1997).
51. Uthaipibull, C. et al. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 307, 1381-1394 (2001).
52. Conway, D. J. et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nature Med. 6, 689-692 (2000).
53. Miller, L. H., Roberts, T., Shahabuddin, M. & McCuthchan, T. F. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol. Biochem. Parasitol. 59, 1-14 (1993).
54. Blackman, M. J., Ling, I. T., Nicholls, S. C. & Holder, A. A. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol. Biochem. Parasitol. 49, 29-33 (1991).
55. 19) induces protective immunity to blood stage malaria infection in mice. Parasite Immunol. 20, 413-120 (1998).
56. Rotman, H. L., Daly, T. M., Clynes, R. & Long, C. A. Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model. J. Immunol. 161, 1908-1912 (1998).
57. Vukovic, P., Hogarth, P. M., Barnes, N., Kaslow, D. C. & Good, M. F. Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of the Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-γRI receptors. Infect. Immun. 68, 3019-3022 (2000).
58. Oeuvray, C. et al. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect. Immun. 68, 2617-2620 (2000).
59. Druilhe, P. & Perignon, J. L. Mechanisms of defence against P. falciparum asexual blood stages in humans. Immunol. Lett. 41, 115-120 (1994).
60. Freeman, R. R. & Holder, A. A. Characteristics of the protective response of BALB/c mice immunized with a purified Plasmodium yoelii schizont antigen. Clin. Exp. Immunol. 54, 609-616 (1983).
61. Tian, J. H. et al. Definition of T cell epitopes within the 19 kDa carboxyl terminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1) and their role in immunity to malaria. Parasite Immunol. 20, 263-278 (1998).
62. H cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19 kDa carboxyl terminal fragment of merozoite surface protein-1. J. Immunol. 162, 7309-7314 (1999).
63. Riley, E. M. et al. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol. 14, 321-337 (1992).
64. Branch, O. H. et al. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am. J. Trop. Med. Hyg. 58, 211-219 (1998).
65. Egan, A. F., Burghaus, P., Druilhe, P., Holder, A. A. & Riley, E. M. Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol. 21, 133-139 (1999).
66. Dodoo, D. et al. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun. 67, 2131-2137 (1999).
67. Marsh, K., Otoo, L., Hayes, R. J., Carson, D. C. & Greenwood, B. M. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans. R. Soc. Trop. Med. Hyg. 83, 293-303 (1989).
68. 19 are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193, 1403-1412 (2001).
69. Stoute, J. A. et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336, 86-91 (1997).
70. Stoute, J. A. et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178, 1139-1144 (1998).
71. Boyle, J. S., Barr, I. G. & Lew, A. M. Strategies for improving responses to DNA vaccines. Mol. Med. 5, 1-8 (1999). By targeting antigen-presenting cells, DNA vaccines can induce far greater antibody responses. This might be crucial to developing successful vaccines against organisms such as malaria.
72. Shi, Y. P. et al. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc. Natl Acad. Sci. USA 96, 1615-1620 (1999).
73. Shi, Y. P. et al. Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate. Vaccine 18, 2902-2914 (2000).
74. Wang, R. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476-480 (1998).
75. Engers, H. D. & Godal, T. Malaria vaccine development: current status. Parasitol. Today 14, 56-64 (1998).
76. James, S. & Miller, L. Malaria vaccine development: Status report. 2000. http:/www.nature.com/nm/special_focus/ malaria/commentaries/malcom
77. Grun, J. L. & Weidanz, W. P. Antibody-independent immunity to reinfection malaria in B-cell-deficient mice. Infect. Immun. 41, 1197-1204 (1983).
78. van der Heyde, H. C., Huszar, D., Woodhouse, C., Manning, D. D. & Weidanz, W. P. The resolution of acute malaria in a definitive model of B cell deficiency, the JHD mouse. J. Immunol. 152, 4557-4562 (1994).
79. von der Weid, T., Honarvar, N. & Langhorne, J. Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J. Immunol. 156, 2510-2516 (1996).
80. Brake, D. A., Long, C. A. & Weidanz, W. P. Adoptive protection against Plasmodium chabaudi adami malaria in athymic nude mice by a cloned T cell line. J. Immunol. 140, 1989-1993 (1988).
81. H2-type T cells can control malaria infections through different mechanisms.
82. H1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice. Parasite Immunol. 19, 111-126 (1997).
83. Stevenson, M. M., Tam, M. F., Wolf, S. F. & Sher, A. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-γ and TNF-α and occurs via a nitric oxide-dependent mechanism. J. Immunol. 155, 2545-2556 (1995).
84. Favila-Castillo, L. et al. Protection of rats against malaria by a transplanted immune spleen. Parasite Immunol. 18, 325-331 (1996).
85. Su, Z. & Stevenson, M. M. Central role of endogenous γ-interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection. Infect. Immun. 68, 4399-4406 (2000).
86. Luty, A. J. et al. Interferon-γ responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J. Infect. Dis. 179, 980-988 (1999).
87. Urban, B. C. et al. Plasmodium felciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 400, 73-77 (1999). Indicates that the maturation of dendritic cells might be impeded by parasitized RBCs, therefore dampening a developing T-cell response to the parasite.
88. van der Heyde, H. C., Elloso, M. M., Chang, W. L., Kaplan, M., Manning, D. D. & Weidanz, W. P. γδ T cells function in cell-mediated immunity to acute blood-stage Plasmodium chabaudi adami malaria. J. Immunol. 154, 3985-3990 (1995).
89. Seixas, E. M. & Langhorne, J. γδ T cells contribute to control of chronic parasitemia in Plasmodium chabaudi infections in mice. J. Immunol. 162, 2837-2841 (1999).
90. Nguyen-Dinh, P. et al. Absence of association between Plasmodium falciparum malaria and human immunodeficiency virus infection in children in Kinshasa, Zaire. Bull. World Health Organ. 65, 607-613 (1987).
91. Simooya, O. O., Mwendapole, R. M., Siziya, S. & Fleming, A. F. Relation between falciparum malaria and HIV seropositivity in Ndola, Zambia. Br. Med. J. 297, 30-31 (1988).
92. Muller, O. & Moser, R. The clinical and parasitological presentation of Plasmodium falciparum malaria in Uganda is unaffected by HIV-1 infection. Trans. R. Soc. Trop. Med. Hyg. 84, 336-338 (1990).
93. Allen, S. et al. Human immunodeficiency virus and malaria in a representative sample of childbearing women in Kigali, Rwanda. J. Infect. Dis. 164, 67-71 (1991).
94. Greenberg, A. E. et al. Plasmodium falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire. A prospective, longitudinal cohort study of 587 children. N. Engl. J. Med. 325, 105-109 (1991).
95. Colebunders, R. et al. Incidence of malaria and efficacy of oral quinine in patients recently infected with human immunodeficiency virus in Kinshasa, Zaire. J. Infect. 21, 167-173 (1990).
96. Kalyesubula, I. et al. Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children. Pediatr. Infect Dis. J. 16, 876-881 (1997).
97. Chandramohan, D. & Greenwood, B. M. Is there an interaction between human immunodeficiency virus and Plasmodium falciparum? Int. J. Epidemiol. 27, 296-301 (1998).
98. Whitworth, J. et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 356, 1051-1056 (2000).
99. Verhoef, H., Veenemans, J. & West, C. E. HIV-1 infection and malaria parasitaemia. Lancet 357, 232-233 (2001).
100. Steketee, R. W. et al. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am. J. Trop. Med. Hyg. 55, 42-49 (1996).
101. Fried, M., Nosten, F., Brockman, A., Brabin, B. J. & Duffy, P. E. Maternal antibodies block malaria. Nature 395, 851-852 (1998).
102. Reeder, J. C. et al. The adhesion of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1. Proc. Natl Acad. Sci. USA 96, 5198-5202 (1999).
103. Buffet, P. A. et al. Plasmodium falciparum domain mediating adhesion to chondroitin sulfate A: a receptor for human placental infection. Proc. Natl Acad. Sci. USA 96, 12743-12748 (1999).
104. Toure-Balde, A. et al. Plasmodium falciparum induces apoptosis in human mononuclear cells. Infect. Immun. 64, 744-750 (1996).
105. Hviid, L. et al. Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated Plasmodium falciparum malaria. Infect. Immun. 65, 4090-4093 (1997).
106. + T cells. This might prove to be a useful parasite-defence mechanism.
107. H1-like T cells simultaneously reduce parasitemia and promote disease. Parasite Immunol. 21, 319-329 (1999).
108. Laveran, A. A new parasite found in the blood of malarial patients. Parasitic origin of malarial attacks. Bull. Mem. Soc. Med. Hop. Paris 17, 158-164 (1880).
109. Ross, R. On some peculiar pigmented cells found in two mosquitos fed on malaria blood. Br. Med. J. 2, 1786-1788 (1897).
110. Russel, P. F., West, L. R., Manwell, R. D. & MacDonald, G. Practical Malariology 13 (Oxford Univ. Press, 1963).
111. Russel, P. F., West, L. R., Manwell, R. D. & MacDonald, G. Practical Malariology 631 (Oxford Univ. Press, 1963).
112. Bruce-Chwatt, L. J. Essential Malariology 301-302 (Alden Press, Oxford, 1985).
113. Fairley, N. H. et al. Sidelights on malaria in man obtained by subinoculation experiments. Trans. R. Soc. Trop. Med. Hyg. 40, 621-676 (1947).
114. Kemp, D. J. et al. Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans. Proc. Natl Acad. Sci. USA 80, 3787-3791 (1983).
115. Ellis, J. et al. Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature 302, 536-538 (1983).